by Dr Jacqueline Gosink Tumour necrosis factor (TNF) inhibitors are increasingly used to treat chronic inflammatory bowel diseases, rheumatic diseases and psoriasis. Continuous drug level monitoring and administration interval adjustment accompanying the treatment with TNF inhibitors is the key to successful, individualized and targeted patient care. Concentrations of the TNF inhibitors adalimumab or infliximab can […]
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/5_FEATURED_ARTICLE.jpg137610003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2021-01-26 17:26:432021-01-28 22:29:56Monitoring therapeutic drug dosage in rheumatic diseases, chronic inflammatory bowel diseases and psoriasis
In August 2020 new guidance was issued by the National Institut e for Health and Care Excellence on the use of high-sensitivity troponin tests for the early rule-out of non-ST-elevation myocardial infarction (NSTEMI). CLI caught up with Heather Read-Harper from Beckman Coulter to find out more about the use of cardiac troponin biomarkers in the […]
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/6_FEATURED_ARTICLE.jpg137610003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2021-01-26 16:00:142021-01-28 22:29:56Insight into high-sensitivity troponin tests for the early rule-out of NSTEMI
ZTA Biotech, a Budapest-based biotech startup has announced the breakthrough development of a COVID-19 antibody (IgG) test using the ELISA protocol. This new detection method represents a great step forward in determining if patients have had COVID-19 and if they might still have immunity to the disease. Early results have proven 100% in specificity after testing 280 samples, and 100% sensitivity by testing 260 samples of recovered and symptomatic patients.
One of the conundrums presented by COVID-19 is that it is not uncommon for patients to present with remarkably low oxygen saturation levels but with very little breathlessness. Additionally, it has been noted that there is an additional risk of stroke in COVID-19 patients (and COVID-19-recovered patients) and that they seem to have what is being referred to as ‘sticky blood’. A recent paper by Professor Yost (Department of Pediatrics, University of Utah School of Medicine, UT, USA) and colleagues ‘Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome’ discusses the role that neutrophil extracellular traps (NETs) can play in the development of these symptoms and prothrombotic disease outcomes. CLI was very fortunate to catch up with Professor Yost to learn more about NETs and their effects in COVID-19 and other conditions.
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-24 00:14:002021-01-18 14:45:12Role of neutrophil extracellular traps in COVID-19 and other disease processes
by Dr Madeleen Bosma Despite intensive anticoagulation therapy and improved mechanical characteristics of the current systems, hemolysis and clot formation are frequent complications in extracorporeal life support (ECLS/ECMO), which is the standard rescue treatment in patients with severely impaired cardiac and/or pulmonary function. The laboratory aspects of monitoring of hemolysis and hypercoagulation in this patient group are discussed in this short review.
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-24 00:13:002021-01-18 14:45:23Progress and challenges in the monitoring of hemolysis and clot formation in patients with extracorporeal life support
by Dr Andrew Lane The emergence of SARS-CoV-2 and its global proliferation has spurred unprecedented efforts by academia and the in vitro diagnostics industry to develop rapid tests that can be used for point-of-care (POC) testing. At the time of writing, over 200 rapid test kits are under development or have already been commercialized for use. Yet, owing to relaxation of regulatory standards and the unprecedented pace at which tests have been developed, many have not been adequately assessed. In this article, Dr Andy Lane explains the role of POC diagnostics for COVID-19 and the improvements needed for their widespread use, including the importance of high-quality reagents.
by Dr Jacqueline Gosink The autoimmunogenic myositides (idiopathic inflammatory myopathies, IIM) constitute a group of systemic autoimmune rheumatic diseases that are characterized by chronic inflammation of muscles. Unfortunately, the general misdiagnosis rate is high resulting in a delay to diagnosis of several years. Moreover, a significant proportion of patients with IIM suffer from a generalized feeling of severe illness due to the damage caused by both the disease and its treatment. Autoantibodies are useful biomarkers to differentiate clinically indistinguishable subforms of IIM. Despite the low prevalences and isolated occurrence of many autoantibodies in IIM, they constitute the basis for serological diagnostics. The diagnostic information is maximized by employing comprehensive multiparametric assays covering both myositis-specific and myositis-associated autoantibodies.
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-24 00:11:002021-01-18 14:45:37Autoantibodies in myositis: An upgrade for comprehensive serological testing
MassTox TDM Series A, Chromsystems’ unique modular system for therapeutic drug monitoring (TDM), has been extended to cover 200 drugs. The most recent extensions are additional neuroleptics and antimycotis, including bromperidol, caspofungin, isavuconazole, flupentixol and many others.
All 200 drugs can be determined with the same chromatographic setup and identical sample preparation. This eliminates the need for column switching or changes at the setup of the mass spectrometer, thereby helping to minimise workload in the laboratory for efficient drug monitoring by LC-MS/MS.
The system consists of the analytical column, the Basic Kit for sample preparation and chromatography as well as 13 individual parameter sets, which contain all relevant multilevel calibrators, quality plasma controls and internal standards.
For more information, visit: https://chromsystems.com Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/1_PRODUCT_CHROMSYSTEMS.jpg33310003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-24 00:10:002021-01-14 11:43:41Chromsystems expands therapeutic drug monitoring by LC-MS/MS to 200 drugs
by Pauline Griffeuille and Dr Sylvain Dulaurent Mass spectrometry (MS) can be combined with a number of chromatographic separation and ionization methods, which results in powerful technologies for both qualitative and quantitative molecular analysis. CLI caught up with Dr Bhattacharyya (Thermo Fisher’s Senior Manager for Clinical Research and Toxicology) to find out more about the past, present and potential future uses of MS in clinical science and diagnostics.
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-24 00:10:002021-01-18 14:45:49Insight into mass spectrometry in clinical science and diagnostics
The FlowSyn Multi-X from Uniqsis takes the drudgery out of reaction optimization – effortlessly converting batch chemistry methods to more efficient, higher yielding flow chemistry protocols.
Flow chemistry in microreactors offers many advantages over batch processing notably better reproducibility and scalability, improved yields and fewer problems with unstable intermediates or exothermic reactions.
The FlowSyn Multi-X uses an enhanced FlowSyn control interface to control either a single or a 4-rack fraction collector thereby enabling a sequence of experiments to be performed without the need for a separate PC. Capable of running unattended, it will perform up to 10 sequential experiments and collect the results as fractions or steady state samples allowing the user to vary the key flow-through parameters (stoichiometry, temperature and residence time) in each case.
The entry-level FlowSyn Multi-X system is compact with an integrated controller enabling the user to quickly explore or optimize reaction conditions. Setting up a series of experiments on the FlowSyn Multi-X system is easy – just follow three simple steps. First, set up a single ‘prototype’ reaction, then set up the fraction collector before selecting ‘Table View’ to edit individual experiments and then press ‘Start’ and walk-away.
The option of a Data Logging Software Package enables the FlowSyn Multi-X to both visualize data in real time and save pressure and temperature traces. Alternatively, the powerful FlowControl II system control software can be selected, which links via Wi-Fi and automatically saves complete experimental procedures with all data, including automation events. FlowControl II allows previous experiments to be reloaded and either viewed or repeated with or without modification.
To expand the capabilities of the FlowSyn Multi-X, additional pumps and reactor modules can be added and sequences of up to 100 individual experiments can be performed.
Designed by a team of experienced flow chemists and engineers, FlowSyn Multi-X is based upon the internationally popular FlowSyn, a fully integrated, easy to use continuous flow reactor for seamless reaction optimization and scale up from milligrams to hundreds of grams.
For more information, visit: www.uniqsis.com Read more
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/5B_PRODUCT_UNIQSIS.jpg8339323wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-24 00:09:002021-01-14 11:43:18Uniqsis introduces multi-experiment flow system for reaction optimization
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Monitoring therapeutic drug dosage in rheumatic diseases, chronic inflammatory bowel diseases and psoriasis
, /in Featured Articles /by 3wmediaby Dr Jacqueline Gosink Tumour necrosis factor (TNF) inhibitors are increasingly used to treat chronic inflammatory bowel diseases, rheumatic diseases and psoriasis. Continuous drug level monitoring and administration interval adjustment accompanying the treatment with TNF inhibitors is the key to successful, individualized and targeted patient care. Concentrations of the TNF inhibitors adalimumab or infliximab can […]
Insight into high-sensitivity troponin tests for the early rule-out of NSTEMI
, /in Featured Articles /by 3wmediaIn August 2020 new guidance was issued by the National Institut e for Health and Care Excellence on the use of high-sensitivity troponin tests for the early rule-out of non-ST-elevation myocardial infarction (NSTEMI). CLI caught up with Heather Read-Harper from Beckman Coulter to find out more about the use of cardiac troponin biomarkers in the […]
Read more
#diagnostics, Clinical, /in No Category, Corona News, E-News, Product News /by panglobalRead more
Role of neutrophil extracellular traps in COVID-19 and other disease processes
, /in E-News, Featured Articles /by 3wmediaOne of the conundrums presented by COVID-19 is that it is not uncommon for patients to present with remarkably low oxygen saturation levels but with very little breathlessness. Additionally, it has been noted that there is an additional risk of stroke in COVID-19 patients (and COVID-19-recovered patients) and that they seem to have what is being referred to as ‘sticky blood’. A recent paper by Professor Yost (Department of Pediatrics, University of Utah School of Medicine, UT, USA) and colleagues ‘Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome’ discusses the role that neutrophil extracellular traps (NETs) can play in the development of these symptoms and prothrombotic disease outcomes. CLI was very fortunate to catch up with Professor Yost to learn more about NETs and their effects in COVID-19 and other conditions.
Read more
Progress and challenges in the monitoring of hemolysis and clot formation in patients with extracorporeal life support
, /in E-News, Featured Articles /by 3wmediaby Dr Madeleen Bosma
Despite intensive anticoagulation therapy and improved mechanical characteristics of the current systems, hemolysis and clot formation are frequent complications in extracorporeal life support (ECLS/ECMO), which is the standard rescue treatment in patients with severely impaired cardiac and/or pulmonary function. The laboratory aspects of monitoring of hemolysis and hypercoagulation in this patient group are discussed in this short review.
Read more
Status of COVID-19 rapid point-of-care immunoassay testing
, /in E-News, Featured Articles /by 3wmediaby Dr Andrew Lane
The emergence of SARS-CoV-2 and its global proliferation has spurred unprecedented efforts by academia and the in vitro diagnostics industry to develop rapid tests that can be used for point-of-care (POC) testing. At the time of writing, over 200 rapid test kits are under development or have already been commercialized for use. Yet, owing to relaxation of regulatory standards and the unprecedented pace at which tests have been developed, many have not been adequately assessed. In this article, Dr Andy Lane explains the role of POC diagnostics for COVID-19 and the improvements needed for their widespread use, including the importance of high-quality reagents.
Read more
Autoantibodies in myositis: An upgrade for comprehensive serological testing
, /in E-News, Featured Articles /by 3wmediaby Dr Jacqueline Gosink
The autoimmunogenic myositides (idiopathic inflammatory myopathies, IIM) constitute a group of systemic autoimmune rheumatic diseases that are characterized by chronic inflammation of muscles. Unfortunately, the general misdiagnosis rate is high resulting in a delay to diagnosis of several years. Moreover, a significant proportion of patients with IIM suffer from a generalized feeling of severe illness due to the damage caused by both the disease and its treatment. Autoantibodies are useful biomarkers to differentiate clinically indistinguishable subforms of IIM. Despite the low prevalences and isolated occurrence of many autoantibodies in IIM, they constitute the basis for serological diagnostics. The diagnostic information is maximized by employing comprehensive multiparametric assays covering both myositis-specific and myositis-associated autoantibodies.
Read more
Chromsystems expands therapeutic drug monitoring by LC-MS/MS to 200 drugs
, /in Product News /by 3wmediaMassTox TDM Series A, Chromsystems’ unique modular system for therapeutic drug monitoring (TDM), has been extended to cover 200 drugs. The most recent extensions are additional neuroleptics and antimycotis, including bromperidol, caspofungin, isavuconazole, flupentixol and many others.
All 200 drugs can be determined with the same chromatographic setup and identical sample preparation. This eliminates the need for column switching or changes at the setup of the mass spectrometer, thereby helping to minimise workload in the laboratory for efficient drug monitoring by LC-MS/MS.
The system consists of the analytical column, the Basic Kit for sample preparation and chromatography as well as 13 individual parameter sets, which contain all relevant multilevel calibrators, quality plasma controls and internal standards.
For more information, visit: https://chromsystems.com
Read more
Insight into mass spectrometry in clinical science and diagnostics
, /in E-News, Featured Articles /by 3wmediaby Pauline Griffeuille and Dr Sylvain Dulaurent
Mass spectrometry (MS) can be combined with a number of chromatographic separation and ionization methods, which results in powerful technologies for both qualitative and quantitative molecular analysis. CLI caught up with Dr Bhattacharyya (Thermo Fisher’s Senior Manager for Clinical Research and Toxicology) to find out more about the past, present and potential future uses of MS in clinical science and diagnostics.
Read more
Uniqsis introduces multi-experiment flow system for reaction optimization
, /in Product News /by 3wmediaThe FlowSyn Multi-X from Uniqsis takes the drudgery out of reaction optimization – effortlessly converting batch chemistry methods to more efficient, higher yielding flow chemistry protocols.
Flow chemistry in microreactors offers many advantages over batch processing notably better reproducibility and scalability, improved yields and fewer problems with unstable intermediates or exothermic reactions.
The FlowSyn Multi-X uses an enhanced FlowSyn control interface to control either a single or a 4-rack fraction collector thereby enabling a sequence of experiments to be performed without the need for a separate PC. Capable of running unattended, it will perform up to 10 sequential experiments and collect the results as fractions or steady state samples allowing the user to vary the key flow-through parameters (stoichiometry, temperature and residence time) in each case.
The entry-level FlowSyn Multi-X system is compact with an integrated controller enabling the user to quickly explore or optimize reaction conditions. Setting up a series of experiments on the FlowSyn Multi-X system is easy – just follow three simple steps. First, set up a single ‘prototype’ reaction, then set up the fraction collector before selecting ‘Table View’ to edit individual experiments and then press ‘Start’ and walk-away.
The option of a Data Logging Software Package enables the FlowSyn Multi-X to both visualize data in real time and save pressure and temperature traces. Alternatively, the powerful FlowControl II system control software can be selected, which links via Wi-Fi and automatically saves complete experimental procedures with all data, including automation events. FlowControl II allows previous experiments to be reloaded and either viewed or repeated with or without modification.
To expand the capabilities of the FlowSyn Multi-X, additional pumps and reactor modules can be added and sequences of up to 100 individual experiments can be performed.
Designed by a team of experienced flow chemists and engineers, FlowSyn Multi-X is based upon the internationally popular FlowSyn, a fully integrated, easy to use continuous flow reactor for seamless reaction optimization and scale up from milligrams to hundreds of grams.
For more information, visit: www.uniqsis.com
Read more